CVS Health Revised GAAP EPS Guidance To $6.37-$6.61 From $6.53-$6.75, Reaffirms Adjusted EPS Guidance Of $8.50-$8.70 Versus Consensus Of $8.58
Portfolio Pulse from Benzinga Newsdesk
CVS Health has revised its GAAP EPS guidance downwards to $6.37-$6.61 from the previous $6.53-$6.75. However, the company has reaffirmed its adjusted EPS guidance of $8.50-$8.70, which is in line with the consensus of $8.58.
November 01, 2023 | 10:38 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
CVS Health has lowered its GAAP EPS guidance, which could potentially impact investor sentiment and the company's stock price.
CVS Health's downward revision of its GAAP EPS guidance could be seen as a negative signal by investors, potentially leading to a decrease in the company's stock price in the short term. However, the reaffirmation of its adjusted EPS guidance might mitigate this impact to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100